CDK4 and breast carcinoma: That said, patients with PIK3CAmut HR+, HER2− advanced breast cancer have been shown to benefit from treatment with the p110α inhibitor alpelisib plus fulvestrant, regardless of prior treatment with a CDK4/6 inhibitor [49, 50].